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http://dx.doi.org/10.1016/j.jmii.2013Background/Purpose: Between 5% and 10% of the vaccinated population responds less well to
standard vaccination schedules irrespective of hepatitis B virus (HBV) vaccination. This manu-
script aims at describing possible correlation of different major histocompatibility complex
(MHC) Class-I and MHC Class-II haplotype to anti-HBV humoral responsiveness following HBV
vaccination.
Materials and Methods: The study was conducted on 944 vaccinated hospital staff members
and concentrated on the 38 nonresponders as defined by enzyme-linked immunosorbent assay
(ELISA) results. In order to define significance of the different haplotypes from the nonre-
sponders, their frequency was compared to the frequency of the same haplotype in 18
randomly selected responders. Human leukocyte antigen (HLA)-A and HLA-B antigens were
typed among total mononuclear cells using a standard two-stage microlymphocytotoxicity
test. The typing method of HLA Class-II is based on a technique that involves amplification
of the second exon of different HLA Class-II genes by PCR.
Results: Positive correlations were found between four HLA-DR (HLA-DRB1*04X, DRB1*0401X,
DRB1*11/13, and DRB1*0401X0201) haplotypes and nonresponders but there was a negative
correlation with one Class-I (HLA-B13).
Conclusion: This study suggested that certain HLA types are associated with nonresponsiveness
to vaccination. The different HLA of ethnic groups should also be kept in mind when evaluatingglam Caddesi, Gu¨lhane Askeri Tıp Faku¨ltesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji AD, 06018
u.tr (A. Karakas).
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should be examined in further large-scale population-based studies.
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reserved.Introduction
Hepatitis B vaccination remains the best tool available to
prevent and control hepatitis B virus (HBV) infection and
related diseases, which still threaten about a million people
worldwide. Recombinant HBV vaccines achieve seropro-
tection in more than 90% of the vaccinated healthy adult
population. The hepatitis B vaccine is considered to be
highly immunogenic and has a good safety record. About
5e10% of the vaccinated population responds less well to
standard vaccination schedules irrespective of hepatitis B
vaccination.1,2
Genetic factors are implicated in the response of normal
individuals to hepatitis B vaccine. Various constitutional
and behavioral factors have been described that could have
a negative influence on the immune response and play a
role in nonresponsiveness; age, male sex, obesity, anti-
human immunodeficiency virus (HIV) seropositivity, and
smoking habits.
The major histocompatibility complex (MHC), termed
the human leukocyte antigen (HLA) region and encoded on
chromosome 6 in humans, is involved in the regulation of
immune responses. General genetic factors and, more
specifically, polymorphisms of the MHC have also been
linked to variation in immune responses. Some studies have
linked the presence or absence of several HLAs to poor
responsiveness after vaccination.3
MHC genes may also control the capability of the hu-
moral response to vaccination. The DPB1*0501 allele is
associated with improved antibody responses to vaccina-
tion with a malaria sporozoite antigen in Thai individuals.4
Hemodialyzed patients either do not respond to or develop
very low antibody titers against significant numbers of
hepatitis B vaccines.5,6 Ethnic differences in HLA pheno-
types may also show hypo- or nonresponsiveness to HBV
vaccination. Weak responsiveness to hepatitis B vaccine is
associated with the DR3 and/or DR7 alleles,7e11 when they
are present on the extended haplotypes HLA B8-DR3-SC01
and HLA B44-DR7-FC31, in Caucasians. Another report has
shown that nonresponsiveness to the hepatitis B vaccine is
strongly associated with the extended HLA haplotype B44;
DRB1*0701, DQB1*0202 genotype.12 In Japanese in-
dividuals, the Bw54-DR4-DQW4 haplotype has been con-
nected with poor vaccine responses.13e15 Nevertheless,
most studies regarded a limited number of alleles and
nonresponders, meaning that the results were rarely sta-
tistically significant.
In this study we sought to investigate efficacy of MHC
and some genetic factors on nonresponsiveness of hep-
atits B vaccination in healthcare workers of our hospital
(Gulhane Military Medical Academy Hospital, Ankara,
Turkey).Methods
Participants
The study was conducted with 38 participants (26 were
male) who were nonresponders to hepatitis B vaccination
among the 944 vaccinated members of the hospital staff.
The hospital’s total number of employees is around 6000.
The nonresponse rate was 4%. Study procedures were
approved by the institutional review board prior to study
initiation. Participants were selected in the routine vacci-
nation program of health officers. Routine informed con-
sent for clinical procedures was obtained by the infectious
disease specialist. All participants were assessed for
smoking habits, obesity, and noncommunicable familial
chronic diseases such as renal, cardiac, hematologic, or
hepatic diseases. Samples were obtained over a 10-month
period. The serological profiles for HBV surface antigen
(HBsAg), anti-HBsAg antibody (anti-HBs), hepatitis B e-an-
tigen, anti-hepatitis B e-antigen, and total anti-HBV core
antibodies of the participants were found to be negative.
Included in the exclusion criteria was the simultaneous
administration of any other vaccine, or participation in
another clinical trial at the time of administration of hep-
atitis B vaccine.
None of the 38 participants, who were enrolled from
medical outpatient services and ranged in age from 20
years to 47 years, were clinically obese, indicated chronic
kidney disease, or had histories of smoking. All individuals
consented to be included in the study. A control group was
randomly selected in which 18 individuals were responders
to heptitis B vaccination, with antibody titers >100 IU/mL.Standard hepatitis B vaccination program
Three doses of S-subunit recombinant hepatitis B vaccine
(20 mg of Engerix B; GlaxoSmithKline, Rixensart, Belgium)
are routinely given to all new staff members working at the
hospital after the determination of absence of HBsAg and
anti-HBs. The protocol involves the application of vaccine
intramuscularly in the deltoid muscle at 0 months, 1 month,
and 6 months. Measurement of serum levels of antibody to
HBsAg serum samples were obtained from vaccinated in-
dividuals 4 weeks after the third vaccination. The levels of
antibody responses specific for HBsAg were assayed by
radioimmunoassay using a commercial test system (Axsym
system, Abbott Laboratories, Abbott Park, IL, USA). The
individuals who had <10 IU/mL anti HBs were accepted as
nonresponders, and those who had >100 IU/mL anti-HBsAg
after the third dose of vaccine, were enrolled as
responders.
Effect of HLA antigens on HBV vaccination 11Determination of HLA Class-I
HLA-A and HLA-B antigens were typed on total mononuclear
cells by the standard two-stage microlymphocytotoxicity
test using extended incubation times of Dyna Beads as
previously described.16
Determination of HLA Class-II
DNA was extracted from peripheral granulocytes using
standard methods. The HLA Class-II (DRB1, DRP1, and
DQB1) was determined with INNO-LIPA DRB (Line Probe
Assay, Catalog numbers 80336, 80340, and 80344; Innoge-
netics, Ghent, Belgium) as developed by Buyse et al.17 This
typing method is based on a technique that involves an
amplification of the second exon of different HLA Class-II
genes by PCR. The amplified DNA was hybridized to
membrane-bound sequence-specific oligonucleotides, and
subsequently visualized by using an alkaline phosphate-
based reaction.
Statistical analysis
In order to determine heterogeneity values for all alleles
detected at each locus, Fisher’s exact tests were used, and
the level of significance was set at p < 0.05. The double-Table 1 Human leukocyte antigen (HLA) Class I antigens in non
HLA Class-I haplotypes
HLA BW6
HLA BW4
HLA CW4
HLA B35
HLA B13
HLA A2
HLA CW6
HLA A11, HLA A26(10)
HLA A24(9)
HLA A11,
HLA A3, HLA A24(9)
HLA B51(5),HLA CW7
HLA A26(10)
HLA B60(40),HLA CW5
HLA A33(19),HLA A1,HLA CW3,HLA CW5
HLA A1
HLA A29(19)
HLA B57(17),
HLA A29(19), HLA B7, HLA B41 HLA B73, HLA CW1
HLA A25(10)
HLA A23(9)
HLA A68(28),HLA A32(19), HLA A30(19),
HLA B50(21), HLA B42, HLA B58(17), HLA B63(15)
HLA A28(68), HLA A(31)19, HLA B52(5), HLA B18
HLA A32, HLA B38(16), HLA B44(12), HLA B8,
HLA B55(22), HLA B24(9), HLA B72(70),
HLA B56(22), HLA B49(21), HLA B73(15), HLA B14,HLA B51(5)
HLA B48, HLA B58(16), HLA B51(22), HLA B63(5)
* p < 0.05.sided statistical method was used, initially for absence of
any foresight. Odds ratios were calculated with Woolf’s
formula and reported with 95% confidence intervals, and
these ratio values reflect the likelihood of carrying a
particular HLA allele in the nonresponder group compared
with the responder group.
Results
Fifty-nine types of antigens were found to possess HLA-Class-
I antigens as detected by theDyna Beads HLA-Class-Imethod.
Seventy types of antigens were positive for HLA-Class-II an-
tigens variable by line probe assay reverse hybridization. The
distribution of HLA Class-I and HLA Class-II antigens in both
case and control groups are presented in Tables 1 and 2. The
average age of the responders was 37 6.9 years. The male-
to-female ratio in the responder (nZ 18) population was 4:1,
while in the nonresponder population it was 2:1. The fre-
quency of specific HLA types among responders and non-
responders are summarized in Tables 1 and 2.
Linked to HLA alleles and anti-HBs antibody
production
The alleles at each HLA locus that either positively or
negatively contributes to the anti-HBs antibody productionresponders and responders to hepatitis B virus vaccination
Nonresponders
n Z 38 (%)
Responders
n Z 18 (%)
p
30 (78.94) 15 (83.33) 0.5007
23 (60.52) 10 (55.55) 0.7410
12 (31.57) 4 (22.22) 0.3478
11 (28.94) 8 (21.05) 0.3815
15 (39.47) 1 (5.55) 0.0072*
15 (39.47) 7 (38.88) 0.6016
9 (23.68) 3 (16.66) 0.4114
7 (18.42) 2 (5.26) 0.3926
7 (18.42) 5 (27.77) 0.8730
7 (18.42) 4 (22.22) 0.7600
7 (18.42) 3 (16.66) 0.5950
6 (18.75) 2 (11.11) 0.4917
5 (13.15) 4 (22.22) 0.8926
4 (10.52) 1 (5.55) 0.4792
4 (10.52) 2 (11.11) 0.7111
4 (10.52) 4 (22.22) 0.1590
3 (7.89) 2 (11.11) 0.8171
3 (7.89) 0 (0.00) 0.3043
3 (7.89) 1 (5.55) 0.6144
2 (5.26) 2 (11.11) 0.2928
2 (5.26) 0 (0.00) 0.4565
2 (5.26) 1 (5.55) 0.7608
1 (2.63) 2 (11.11) 0.2392
1 (2.63) 1 (5.55) 0.4441
0 (0.00) 1 (5.55) 0.3214
Table 2 Human histocompatibility leukocyte antigen (HLA) Class II antigens in nonresponders and responders to hepatitis B
virus vaccination
HLA Class-II haplotypes Nonresponders, n Z 38 (%) Responders, n Z 18 (%) p
DPB1*0401X0201 8 (21.05) 9 (50.00) 0.0309*
DRB1*07X 8 (21.05) 2 (11.11) 0.3058
DQB1*020102X 7 (18.42) 0 (0.00) 0.0544
DRB1*11X 6 (18.75) 2 (11.11) 0.4917
DRB1*13 5 (13.15) 1 (5.55) 0.3633
DQB1*0301, DQB1*0301X 5 (13.15) 0 (0.00) 0.1314
DRB1*04 4 (10.52) 2 (11.11) 0.6367
DRB1*01X 4 (10.52) 1 (5,55) 0.4792
DRB1*01X, DQB1*0302, DQB1*0501X 4 (10.52) 0 (0.00) 0.2010
DRB1*04X 3 (7.89) 8 (44.44) 0.0027*
DPB1*0401X2301 3 (7.89) 1 (5.55) 0.6144
DPB1*2301X5101, DQB1*0201X 3 (7.89) 0 (0.00) 0.3043
DRB1*0401X 2 (5.26) 5 (27.77) 0.0292*
DRB1*16, DPB1*0401X0402 2 (5.26) 2 (11.11) 0.3856
DRB1*14 DPB1*0301X DPB1*1011 2 (5.26) 1 (5.55) 0.6957
DRB1*03 DRB1*03X DRB1*12 DPB1*0301
DPB1*0402X5101 DPB1*2301 DPB1*0501-3801
DQB1*06011X DQB1*0402X DQB1*0305X
2 (5.26) 0 (0.00) 0.4565
DRB1*11/13 1 (2.63) 4 (22.22) 0.0327*
DPB1*1701 1 (2.63) 2 (11.11) 0.2392
DRB1*16X DRB1*11 DRB1*16/15 DRB1*07
DRB1*08 DPB1*5101
1 (2.63) 1 (5.55) 0.5435
DRB1*2X, DPB1*12/4101, DPB1*0402X,
DPB1*5001X0401 DPB1*0402, DPB1*2012X0301,
DPB1*0402X2901, DPB1*2501X4601, DPB1*3301X0402,
DPB1*0402X, DPB1*0401X3801, DPB1* 1601X,
DPB1*1601, DQB1*0401, DQB1*6011,12, DQB1*0603X,
DPB1*0401X0402
1 (2.63) 0 (0.00) 0.6786
DRB1*15; 0 (0.00) 2 (11.11) 0.0994
DRB1*13/14; DRB1*14X; DRB1*15X; DPB1*1401(2);
DPB1*1501; DPB1*0401; DPB1*0402X4101
0 (0) 1 (5.55) 0.3214
DRB1*13/3; DPB1*0201X2; DPB1*11011; DPB1*1301X;
DPB1*0401X0501; DPB1*20123201; DPB1*1011,12X;
DPB*2301X5101; DPB*0501,3801X; DP*0402X02011;
DP*0402X0201112320
0 (0) 0 (0.00) 1
* p < 0.05.
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efficients of these alleles are listed in Tables 1 and 2. In the
HLA-A and HLA-B loci, HLA-B13 contributed negatively to
the anti-HBs antibody response (p Z 0.072). HLA-B13 was
more frequent in the nonresponders (15/38, 39.5%)
compared to the responders (1/18, 5.6%). In the HLA-DRB1
locus, HLA-DRB1*04X, DRB1*0401X, DRB1*11/13, and
DRB1*0401X0201 positively contributed to the response.
HLA-DRB1*04X (3/38, 7.89%), DRB1*0401X (2/38, 5.26%),
DRB1*11/13 (1/38, 2.63%), and DRB1*0401X0201 (8/38,
21.05%) were less frequent in the nonresponders, whereas
the distribution of the same alleles were more frequent in
the responders, 44%, 27,7%, 22.22%, and 50%, respectively.
Haplotypes with the highest frequencies among non-
responders (compared to responders) were HLA B60 (40),
HLA CW5, DRB1*01X, DRB1*07X, and DRB1*13 (2 times more
frequent). By contrast, HLA A28 (68), HLA A (31)19, HLA B52
(5), HLA B18, and DPB1*1701 were 2.5 times more frequentamong the responders. However, these differences in fre-
quencies were not significant.Discussion
Although the effects of HLA types of immune responses
could not be fully defined, certain HLA types have been
found to be associated with nonresponsiveness to vacci-
nation.18e20 Some risk factors that have been associated
with nonresponsiveness to HBV vaccine include male sex,
obesity, increasing age, cigarette smoking, the gluteal
administration of the vaccine,21,22 chronic renal failure,
and diabetes.23 The relationship of HBV vaccination
response with HLA types is under investigation and there
are a limited number of studies on the subject in Turkey.
The generation of a successful anti-HBs response re-
quires cooperation between HBsAg-specific T and B
Effect of HLA antigens on HBV vaccination 13lymphocytes. It can be hypothesized that a reduction or
absence of one or both of these components may lead to a
defective or absent anti HBs response.24 The lymphocytes
from most of the good responders to HBV vaccine prolif-
erated in vitro upon stimulation with HBsAg particles,
whereas the lymphocytes from the majority of intermedi-
ate or poor/nonresponders generally do not react upon
stimulation with HBsAg. It is possible that nonresponders
are defective in the presentation of HBsAg.
On the basis of HLA-A, HLA-B, and HLA-C phenotype
frequencies, the Turkish population can be compared to
European whites, Japanese, blacks, and also Greek and
Tunisian populations.25,26 Turks appear to have patterns
similar to European Caucasoid and Greek populations for
HLA-A phenotypes.27 In the Japanese, however, HLA-A1 is
lower than in other populations. The most common A and B
locus antigens for Turkish and white Europeans are A2, A9,
B5, B35, and B12, respectively.28 In contrast to those find-
ings most commonly observed locus antigens for our study
population were HLA BW6, HLA BW4, and DPB1. Although
the study population included in the previous study28
mainly consisted of people living in the west part of
Turkey, the majority of this study participants came from
central and eastern parts of Turkey. From that point of view
we speculate that geographical difference may be associ-
ated with the different HLA haplotypes found in the current
study. In the Japanese population, B5, B40, and B15 are the
most common B locus antigens. In blacks, B12, B5, and B7
are the more common B locus antigens. The less common B
locus antigen is B15 for Turkish, B14 for white Europeans,
B13 for Greeks and blacks, and B18 for the Japanese.29
The weak responsiveness to HBsAg vaccine is associ-
ated with the DR3 and/or DR7 alleles,7e11 when they are
present on the extended haplotypes HLA B8-DR3-SC01 and
HLA B44-DR7-FC31 in Caucasians. Our results reveal that
extended haplotypes HLA-DRB1*04X, DRB1*0401X,
DRB1*11/13, and DRB1*0401X0201 are significantly asso-
ciated with antibody response to the HBV vaccine. The
haplotypes described above have not been reported in
other investigations. HLA A1 was at a high frequency in
responders such as DQ2, DQ3, DR3, B44, DR4, and DR53 in
other investigations. In this study it was found that HLA A1
frequencies were not significantly different in both re-
sponders and nonresponders, consistent with other
reports.30,31
The HLA B13 haplotype was associated with non-
responsiveness to vaccination in our participants, which
to-date has not been reported by others. Certain HLA
haplotypes such as B46 and B15 were higher in non-
responders as previously reported.31 However, the fre-
quency of HLA B15 is considerably low in the Turkish
general population, and the coding for this antigen was not
detected in our participants.29 Our results indicate that
the different HLA gene frequencies of ethnic groups should
be considered for further larger population based re-
sponders and nonresponders.Limitations and restrictions
The control group included a limited number of partici-
pants, did not cover the generally Turkish population (onlythe Central Anatolia of Turkey), and was of small sample
size.
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